Roche presents positive late-stage Hemlibra data
Haemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly.
Read More
Tag: HAVEN
Trial findings back wider use of Roche’s Hemlibra
Data from two late-stage studies further support use of Roche’s Hemlibra in a much broader population of haemophilia patients.
Read More
Roche’s Hemlibra reduces bleeds in haemophilia A patients
Roche’s Hemlibra has hit key targets in a Phase III trial assessing its effectiveness in preventing bleeds in adults and adolescents with haemophilia A without inhibitors to factor VIII.
Read More
Roche’s haemophilia drug cut bleeds by 87 percent in trial
Roche has presented a new batch of data showing that its experimental bispecific monoclonal antibody emicizumab significantly reduced bleeds in patients with haemophilia A and inhibitors to factor VIII.
Read More
